ABIONYX Pharma Logo

ABIONYX Pharma

Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.

ABNX | PA

Overview

Corporate Details

ISIN(s):
FR0012616852 (+1 more)
LEI:
969500785J7VIC5YPC96
Country:
France
Address:
33 AVENUE GEORGES POMPIDOU, 31130 BALMA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ABIONYX Pharma is a new-generation biotechnology company focused on discovering and developing innovative therapies for diseases with no existing or effective treatments, including rare conditions. The company specializes in creating drugs for renal and ophthalmological diseases. It leverages its expertise in lipid science to develop novel treatments, including new High-Density Lipoprotein (HDL) vectors for targeted drug delivery and apolipoprotein A-I (apoA-I)-based therapeutics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 18:49
Regulatory News Service
Inside Information / Other news releases
English 253.1 KB
2025-10-21 18:49
Regulatory News Service
Informations privilégiées / Autres communiqués
French 336.0 KB
2025-09-25 18:58
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
French 1.0 MB
2025-08-28 18:51
Earnings Release
Inside Information / Other news releases
English 303.6 KB
2025-08-28 18:51
Earnings Release
Informations privilégiées / Autres communiqués
French 336.5 KB
2025-08-27 19:26
M&A Activity
Informations privilégiées / Autres communiqués
French 274.8 KB
2025-08-27 19:26
M&A Activity
Inside Information / Other news releases
English 236.5 KB
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 217.2 KB
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.1 KB
2025-07-03 19:35
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 532.3 KB
2025-07-03 19:35
Capital/Financing Update
Acquisition or disposal of the issuer's own shares / Information relating to th…
English 557.0 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Inside Information / Other news releases
English 206.8 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 221.2 KB
2025-06-06 18:15
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 273.9 KB
2025-06-03 18:00
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.3 KB

Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ABIONYX Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-28 N/A Other Buy 53,913 N/A

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.